Showing 5281-5290 of 10451 results for "".
- Economic Analysis Shows Wide Range in Annual Sunscreen Expenseshttps://practicaldermatology.com/news/economic-analysis-shows-wide-range-in-annual-sunscreen-expenses/2485778/A new 2025 economic evaluation of annual sunscreen costs found wide variation depending on unit pricing and clothing coverage. Investigators conducted the analysis from July through August 2025, modeling the cost of sunscreen
- Report: Skin Lightening Resurgence Raises Safety Concernshttps://practicaldermatology.com/news/report-skin-lightening-resurgence-raises-safety-concerns/2485703/A growing global resurgence in skin lightening (SL) practices is raising renewed safety and public health concerns, according to a recent publication in the Journal of the American Academy of Dermatology.
- AI Footprint Grows in Aesthetic Surgery: Analysishttps://practicaldermatology.com/news/ai-footprint-grows-in-aesthetic-surgery-specialty-analysis/2485685/Artificial intelligence (AI) is increasingly embedded in plastic surgery, according to a narrative review published in Aesthetic Surgery Journal. Authors used PubMed searches of arti
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Study: HS Linked to Hyperglycemia and Altered Amino Acid Metabolism in Plasmahttps://practicaldermatology.com/news/study-hs-linked-to-hyperglycemia-and-altered-amino-acid-metabolism-in-plasma/2485657/New research in the Archives of Dermatological Research shows consistent metabolic alterations in patients with moderate-to-severe hidradenitis suppurativa (HS, particiularly regarding energy and amino acid metabolism, that
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Danish Registry Study Shows Rising cSCC and CIS Incidence Over 18 Yearshttps://practicaldermatology.com/news/nearly-two-decades-of-data-highlight-shifting-patterns-in-keratinocyte-neoplasms/2485635/Incidence rates of cutaneous squamous cell carcinoma (cSCC) and cSCC in situ (CIS) have continued to rise in Denmark over nearly two decades, while keratoacanthoma (KA) incidence has declined, according to a large population-based registry study.
- Staphylococcus aureus Implicated as Central Driver of Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/staphylococcus-aureus-implicated-as-central-driver-of-pediatric-atopic-dermatitis/2485614/A comprehensive literature analysis presented at the South Beach Symposium identified Staphylococcus aureus as a key contributor to pediatric atopic dermatitis (AD) pathogenesis, extending beyond disease exacerbation to underlying inflammation and prurit
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April